ARTICLE | Company News
Maxygen allergy deal with ALK-Abello
February 8, 2001 8:00 AM UTC
MAXY and ALK-Abello, a subsidiary of Chr. Hansen Holding (CSE:CHRH), will develop recombinant allergy therapeutics. The three-year deal will combine MAXY's MolecularBreeding directed evolution technol...